We have previously reported that 5-ASA, a key drug in IBD, induces the cluster of differentiation (CD)4+-/CD25+-/Foxp3+ regulatory T cells (Tregs) that suppress inflammation via the aryl hydrocarbon receptor (AhR), making it a potential new therapeutic target in the treatment of IBD [6]. Here, AHR is linked to inflammatory bowel disease.